格隆汇12月29日丨微泰医疗-B(02235.HK)公告，12月29日耗资23.5万港元回购3.05万股。 ...

微泰医疗-B(02235)发布公告，于2025年12月29日，该公司斥资23.47万港元回购3.05万股。 ...

智通财经APP讯，微泰医疗-B(02235)发布公告，于2025年12月29日，该公司斥资23.47万港元回购3.05万 股。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 微泰醫療器械（杭州）股份有限公司（於中華人民共和國註冊成立） 呈交日期： 2025年12月29日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02235 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有 ...

微 泰 醫 療 器 械（ 杭 州 ）股 份 有 限 公 司 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號： 2235） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 MicroTech Medical (Hangzhou) Co., Ltd. II. 臨時股東大會的表決結果 | | 普通決議案 | | 有效票數及所佔投票總數百分比（%） | | 總票數 | | --- | --- | --- | --- | --- | --- | | | | 贊成 | 反對 | 棄權 | | | 1. | 待股份激勵計劃獲採納後， | 287,520,846 | 11,522,346 | 1,146,835 | 300,190,027 | | | 審議並通過股東向董事會及╱ | 95.78% | 3.84% | 0.38% | | | | 或管理委員會授出授權以辦 | | | | | | | 理股份激勵計劃相關事宜 ...

Core Viewpoint - The company, Microtech Medical-B (02235), has received approval for its LinX continuous glucose monitoring system in Brazil, which is expected to enhance its market presence in Latin America and drive revenue growth [1]. Group 1: Company Performance - As of December 24, 2025, the stock closed at 7.68 yuan, reflecting a 0.52% increase from the previous trading day [1]. - The stock's 52-week high is 9.17 yuan, while the low is 4.0 yuan [1]. Group 2: Market Opportunity - Brazil is identified as a core market in Latin America, with approximately 16.62 million diabetes patients aged 20-79, representing a prevalence rate of 10.7%, ranking sixth globally [1]. - Diabetes-related expenditures in Brazil are projected to reach approximately $45.1 billion in 2024, making it the third highest globally [1]. Group 3: Strategic Focus - The company aims to continue focusing on technological innovation and global development in the diabetes monitoring, treatment, and management sectors [1].

Core Viewpoint - MicroTech Medical-B (02235.HK) has received approval for its LinX continuous glucose monitoring system in Brazil, targeting both adults and children for dynamic blood glucose monitoring [1] Market Potential - Brazil is identified as a core market in Latin America with significant potential, housing approximately 16.62 million diabetes patients aged 20-79, representing a prevalence rate of 10.7%, ranking sixth globally [1] - Diabetes-related expenditures in Brazil are projected to reach approximately $45.1 billion in 2024, making it the third highest globally, following the United States and China [1] Strategic Implications - The approval of the LinX continuous glucose monitoring system in Brazil is expected to significantly enhance the company's market presence in Latin America, laying a solid foundation for the scaling of international operations and revenue growth [1] - The company plans to continue focusing on the global development of diabetes monitoring, treatment, and management, while driving innovation in related technologies and products [1]

Core Viewpoint - MicroTech Medical-B (02235) has received approval for its LinX continuous glucose monitoring system in Brazil, which is applicable for both adults and children, significantly enhancing the company's market presence in Latin America [1] Group 1: Product Approval - The LinX continuous glucose monitoring system has been approved for sale in Brazil, marking a key milestone for the company [1] - This approval is expected to strengthen the company's market positioning in Latin America [1] Group 2: Business Expansion - The approval lays a solid foundation for the company's international business expansion and revenue growth [1] - The company will continue to focus on the global development of diabetes monitoring, treatment, and management [1] Group 3: Innovation Focus - The company aims to drive ongoing technological and product innovation in the relevant fields [1]

Core Viewpoint - The company has received approval for its LinX continuous glucose monitoring system in Brazil, which will significantly enhance its market presence in Latin America and support international business expansion and revenue growth [1] Group 1: Product Approval - The LinX continuous glucose monitoring system is now approved for use in both adults and children in Brazil [1] Group 2: Market Impact - The approval is expected to strengthen the company's market positioning in Latin America, laying a solid foundation for scaling international operations and increasing revenue [1] Group 3: Future Focus - The company will continue to focus on the global development of diabetes monitoring, treatment, and management, while driving innovation in related technologies and products [1]

MicroTech Medical (Hangzhou) Co., Ltd. 微 泰 醫 療 器 械（ 杭 州 ）股 份 有 限 公 司 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號： 2235） 自願性公告 本公司持續葡萄糖監測系統海外獲批 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 （ 本公司提醒廣大投資者，上述產品的生產、銷售，以及帶來的收益均受市場變 化等多因素影響。本公司股東及潛在投資者於買賣本公司股份時務請審慎行事。 承董事會命 微泰醫療器械（杭州）股份有限公司 董事長 本公告乃微泰醫療器械（杭州）股份有限公司（「本公司」及其附屬公司，「本集 團」）自願發佈，以向本公司股東及潛在投資者提供有關本集團的最新發展。 本公司董事（「董事」）會（「董事會」）欣然宣佈，我們的LinX持續葡萄糖監測系 統，近期獲得巴西的上市批准，適用於成人及兒童的連續動態血糖監測。 巴西作為拉丁美洲的核心市場，具備巨 ...